Jefferies analyst Peter Welford raised the firm’s price target on Novo Nordisk to DKK 575 from DKK 530 and keeps an Underperform rating on the shares. Q2 sales due on August 7 are likely to meet consensus, with profits also broadly in-line once consensus reflects the recent DKK 5.7B impairment, the analyst tells investors in a preview note for the EU pharma group.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk Stock (NYSE:NVO): Can Wegovy Justify Its Valuation?
- Novo Nordisk price target raised to DKK 1,100 from DKK 795 at UBS
- 2seventy Bio announces sale of Hemophilia A candidate for up to $40M
- Novo Nordisk Halts Trial, Faces Financial Setback
- Novo Nordisk kidney failure only ‘modest negative,’ says BMO Capital
Questions or Comments about the article? Write to editor@tipranks.com